Epidemioloxía Cardiovascular, Atención Primaria e Enfermería
Fundación Jiménez Díaz
Madrid, EspañaPublicacións en colaboración con investigadores/as de Fundación Jiménez Díaz (22)
2023
-
Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort
International Journal of Infectious Diseases, Vol. 137, pp. 134-143
-
Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study
European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328
2022
-
Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria
Open Forum Infectious Diseases, Vol. 9, Núm. 9
2021
-
Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study
Atherosclerosis, Vol. 317, pp. 52-58
-
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience
Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592
-
Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia
European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211
2020
-
Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry
Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834
2019
-
Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study
Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996
2018
-
Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study
Journal of Clinical Lipidology, Vol. 12, Núm. 4, pp. 948-957
2017
-
Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART
Revista Espanola de Cardiologia, Vol. 70, Núm. 6, pp. 444-450
-
Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)
Circulation, Vol. 135, Núm. 22, pp. 2133-2144
2016
-
Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up
Journal of the American College of Cardiology, Vol. 67, Núm. 11, pp. 1278-1285
-
Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry
Journal of Clinical Lipidology, Vol. 10, Núm. 4, pp. 953-961
-
Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: Insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study)
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 36, Núm. 9, pp. 2004-2010
-
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
Atherosclerosis, Vol. 254, pp. 249-253
2015
2014
-
Hiperlipidemia familiar combinada: documento de consenso
Atencion Primaria, Vol. 46, Núm. 8, pp. 440-446
-
Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation
Journal of the American College of Cardiology, Vol. 63, Núm. 19, pp. 1982-1989
2008
-
Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors
Atherosclerosis, Vol. 200, Núm. 2, pp. 315-321
2005
-
Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia
Human Biology, Vol. 77, Núm. 5, pp. 663-673